Promising findings for novel drug-eluting peripheral stent.
Ngày 06/08/2016 11:56 | Lượt xem: 1401

A new animal study, presented at EuroPCR (17–20 May, Paris), indicates that a novel, fluoropolymer-coated, self-expanding, paclitaxel-eluting peripheral stent (Eluvia, Boston Scientific) is associated with significantly less neointima at 90 days than is a no polymer, paclitaxel-eluting peripheral stent (Zilver PTX, Cook Medical). Eluvia, which is CE marked but an investigational device in the USA, was also associated with more uniform neointimal coverage.

Speaking on behalf of Juan Granada (CRF Skirball Center for Inovation, New York, USA) at EuroPCR, Thomas Zeller (Department of Angiology, Universitäts-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany) reported that preclinical data for Eluvia have already shown that due to its polymer coating it releases paclitaxel “steadily” and the amount of paclitaxel found in the heart, liver, and systemic blood “are below quantifiable” levels.

“Neointimal thickness is significantly inhibited by the fluoropolymer-coated, paclitaxel-eluting stent compared with a bare metal stent at 30 and 90 days, yielding reductions of in-stent stenosis by 48.1% and 51.9% for the fluoropolymer-coated paclitaxel-eluting stents vs. bare metal stents,” he added.

In this present study, 18 swine with familial hypercholesterolaemia received in an 1:1:1 ratio a bare metal stent, a Zilver PTX drug-eluting stent, or an Eluvia stent—with Zeller explaining that a familial hypercholesterolaemia swine model predicts “antirestenotic efficacy of peripheral drug-coated balloon in a dose-dependent manner”. The swine were then assessed at 30 and 90 days with optical coherence tomography (OCT) and quantitative vascular angiography (additional follow-up at 180 days is also planned). Zeller commented: “In the 30-day imaging data, both the Zilver PTX and Eluvia drug-eluting stent achieved profound antirestenotic effect in comparison to the bare metal stent”. According to the OCT findings, at 30 days, per cent diameter stenosis, late lumen loss, neointimal area, per cent area stenosis were all significantly lower with the paclitaxel-eluting stents compared with the bare metal stent.

However, at 90 days (when imaging data were available for half of the animals), Eluvia was associated with significantly lower area stenosis than both the Zilver PTX stent and the bare stent (30±9% vs. 53±12% vs.78±22%, respectively; p<0.01), and it was also associated with lower mean neointimal thickness than both devices (0.50±0.16mm vs. 0.89±0.24mm vs. 1.29±0.51mm, respectively; p<0.01). “The pattern of neointimal coverage appears more uniform longitudinally in Eluvia when compared to Zilver PTX,” Zeller noted.

He concluded: “The pending 180-day data will further inform the comparative differences in healing and neointimal suppression in this disease model.”

Zeller told Interventional News that the MAJESTIC study—a multicentre, single-arm study that included 57 patients—has also indicated that use of Eluvia (in humans) results in durable clinical improvement at one-year follow-up with a primary patency rate of 96.1% and a freedom from target lesion revascularisation rate of 96.2%. The two- and three-year follow-up is still pending. He added: “Another prospective trial (IMPERIAL), is still recruiting patients. The trial is randomly comparing Eluvia and Zilver PTX drug-eluting stents in patients with superficial femoral artery lesions.”

Vascularnews.com

Print Chia sẽ qua facebook bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua google bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua twitter bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua MySpace bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua LinkedIn bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua stumbleupon bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua icio bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua digg bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua yahoo bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua yahoo bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua yahoo bài: Promising findings for novel drug-eluting peripheral stent. Chia sẽ qua yahoo bài: Promising findings for novel drug-eluting peripheral stent.

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
TOP